Last summer, I asked Sarah a questions about what differentiates Resverlogix from Zenith. She responded: 

"The IP owned by each company is based on composition claims (chemical structure). The IP does not overlap or shift around between the two companies based on indications, and both companies have all rights to their own IP.  Both companies have compounds with different characteristics, including BET inhibitors with different selectivity profiles.  The field of BET bromodomain inhibition is still in its infancy and published data suggest that BETi might have clinical application in a wider range of indications.  Both companies are interested in expanding their platforms based on the activity and properties of their own compounds."

Still, I think it makes sense in some ways to have one larger BET inhibitor powerhouse as opposed to two smaller companies. 

BearDownAZ